Balaxi Pharmaceuticals Limited (IN:BALAXI)
:BALAXI
Want to see IN:BALAXI full AI Analyst Report?
BALAXI Stock Chart & Stats
₹27.06
-₹2.28(-2.93%)
At close: 4:00 PM EST
₹27.06
-₹2.28(-2.93%)
Day’s Range― - ―
52-Week Range₹15.20 - ₹63.90
Previous CloseN/A
Volume27.88K
Average Volume (3M)75.37K
Market Cap
₹1.47B
Enterprise Value₹473.78M
Total Cash (Recent Filing)₹388.49M
Total Debt (Recent Filing)₹565.23M
Price to Earnings (P/E)112.0
Beta1.07
Next Earnings
Jun 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding55,207,500
10 Day Avg. Volume158,740
30 Day Avg. Volume75,367
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)1.60
Price to Sales (P/S)1.28
P/FCF Ratio-6.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth TrajectoryA clear revenue growth trajectory between 2024 and 2025 signals expanding market acceptance of Balaxi's formulations and distribution reach. Durable top-line expansion supports reinvestment in marketing and distribution, improving scale economics and long-term competitive positioning.
Solid Gross And EBIT MarginsSustained gross and EBIT margins indicate structural operational efficiency and pricing discipline in the formulations business. Reliable underlying margins provide resilience to input cost swings and underpin the company's ability to convert revenue into operational profitability as it scales.
Historically Low Leverage / Strong Equity BaseA healthy equity ratio and historically low debt-to-equity give Balaxi financial flexibility to fund growth or absorb shocks without immediate refinancing. This strong capital structure supports strategic investments in distribution and product promotion over the medium term.
Bears Say
Negative Free Cash Flow In 2025Negative free cash flow in 2025, driven by rising capex and negative operating cash flow, weakens internal funding capacity. If persistent, this forces reliance on external financing or asset sales, constraining reinvestment and increasing execution risk for growth plans over the medium term.
Substantial Increase In Total Debt (2025)A marked rise in total debt in 2025 increases leverage after a period of low indebtedness, reducing financial flexibility. Higher debt elevates interest burdens and sensitivity to cash-flow shortfalls, making the company more vulnerable to margin compression or operational setbacks.
Volatile Net Income / Inconsistent Net MarginsSignificant volatility in net income and inconsistent net margins undermines earnings quality and forecasting reliability. This variability raises execution risk for strategic plans, complicates capital allocation decisions, and can weaken stakeholder confidence in medium-term earnings sustainability.
Balaxi Pharmaceuticals Limited News
BALAXI FAQ
What was Balaxi Pharmaceuticals Limited’s price range in the past 12 months?
Balaxi Pharmaceuticals Limited lowest stock price was ₹15.20 and its highest was ₹63.90 in the past 12 months.
What is Balaxi Pharmaceuticals Limited’s market cap?
Balaxi Pharmaceuticals Limited’s market cap is ₹1.47B.
When is Balaxi Pharmaceuticals Limited’s upcoming earnings report date?
Balaxi Pharmaceuticals Limited’s upcoming earnings report date is Jun 03, 2026 which is in 34 days.
How were Balaxi Pharmaceuticals Limited’s earnings last quarter?
Currently, no data Available
Is Balaxi Pharmaceuticals Limited overvalued?
According to Wall Street analysts Balaxi Pharmaceuticals Limited’s price is currently Overvalued.
Does Balaxi Pharmaceuticals Limited pay dividends?
Balaxi Pharmaceuticals Limited pays a Notavailable dividend of ₹0.5 which represents an annual dividend yield of N/A. See more information on Balaxi Pharmaceuticals Limited dividends here
What is Balaxi Pharmaceuticals Limited’s EPS estimate?
Balaxi Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Balaxi Pharmaceuticals Limited have?
Balaxi Pharmaceuticals Limited has 55,207,500 shares outstanding.
What happened to Balaxi Pharmaceuticals Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Balaxi Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:BALAXI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Balaxi Pharmaceuticals Limited
Balaxi Ventures Ltd. engages in the wholesale trading of pharmaceuticals, food products, and hardware. The company is headquartered in Hyderabad, Telangana. The Company’s products include pharmaceuticals products, food products and builders’ hardware products. The company operates through the operating segment international wholesale trading. Its pharmaceutical formulations and builders’ hardware products are contract manufactured from manufacturing plants in India. The firm offers a range of food and biscuit products under the brand name YAP. Its subsidiaries include Balaxi Global DMCC.
Technical Analysis
Biofil Chemicals & Pharmaceuticals Ltd.
―
Gkb Ophthalmics Limited
―
―
Lasa Supergenerics Ltd.
―
Vivimed Labs Limited
―